Received Jun 30, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
he developed at Guillain barre syndrome; he still paralyzed after a year; This serious case was reported by a consumer and described the occurrence of guillain barre syndrome in a adult male patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced guillain barre syndrome (Verbatim: he developed at Guillain barre syndrome) (serious criteria disability and GSK medically significant) and paralysis (Verbatim: he still paralyzed after a year) (serious criteria disability and GSK medically significant). The outcome of the guillain barre syndrome and paralysis were not resolved. The reporter considered the guillain barre syndrome and paralysis to be related to Shingrix. The company considered the guillain barre syndrome and paralysis to be related to Shingrix. Additional Information: GSK Receipt Date:25-JUN-2026 The reporter stated that their friend took vaccine and developed at Guillain Barre syndrome and he is still paralyzed after a year. The reporter stated that they do not wish to take any risks by receiving the vaccine. The batch number was not provided, and we are unable to contact the reporter.; Sender's Comments: A case of Guillain-Barre syndrome (Not meeting BC criteria) and Paralysis, unknown time after vaccination with Shingrix, in a adult male patient. Based on the available information a possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow-up has not been received.